Global Supporters

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

To learn more, visit www.astrazeneca.com and follow AstraZeneca on Twitter and LinkedIn

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. Specific to renal, we have partnered with the nephrology community to focus on pioneering care in both hemodialysis (HD) and peritoneal dialysis (PD); and we maintain that pioneering spirit today through new therapies like expanded hemodialysis (HDx) and remote patient management.

To learn more, visit www.baxter.com and follow Baxter on Twitter, LinkedIn and Facebook.

About Bayer’s Commitment in Cardiovascular and Kidney Diseases

Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular diseases are treated.

Find more information at www.ckd-info.com

Follow us on Twitter: @KidneyDiseaseFm

Follow us on Facebook: https://www.facebook.com/KidneyDiseaseForum/

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com

Follow Boehringer Ingelheim on Twitter, Facebook, LinkedIn and Instagram

At Calliditas Therapeutics, we harness scientific and commercial expertise to improve the lives of patients.  Calliditas is dedicated to expanding treatment options and establishing new standards of care for people with rare diseases. By drawing on our expertise in pharmaceutical product development and leveraging our strategic partnerships, we quickly and efficiently identify, develop, and market a pipeline of innovative medicines that can improve the lives of patients. Recently, we successfully commercialized our lead candidate in the United States, and in collaboration with our partners, launched in Europe, with plans to seek approval in Asia.

To learn more, visit www.calliditas.se or follow us on LinkedIn or Twitter

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.

With its corporate philosophy of “caring for life”, the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

For more information, please visit www.fresenius-kabi.com.

Follow us on social media:

• Facebook:  (20+) Fresenius Kabi | Facebook
• Instagram: https://www.instagram.com/freseniuskabi
• LinkedIn: https://www.linkedin.com/company/freseniuskabi
• Twitter: Fresenius Kabi (@FreseniusKabi) / Twitter
• YouTube: Fresenius Kabi AG – YouTube

Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 3.8 million patients worldwide regularly undergo dialysis treatment. Through its network of more than 4,160 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 346,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the field of critical care.

www.freseniusmedicalcare.com

GSK is a science-led global healthcare company. For further information please visit www.gsk.com/about-us

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension.

Learn more at www.janssen.com.

Follow us at www.twitter.com/JanssenGlobal.

Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.

Website: https://www.novartis.com
Twitter https://twitter.com/novartis
Facebook https://www.facebook.com/novartis
Instagram https://www.instagram.com/novartis/
LinkedIn https://www.linkedin.com/company/novartis/
YouTube https://www.youtube.com/user/Novartis

Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

Learn more at www.sanofigenzyme.com.

At Travere Therapeutics we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.

Website: www.travere.com

Meet Gisela: A journey with IgA nephropathy

Meet Tiffany: Managing a diagnosis of FSGS that came during COVID-19

Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. For more information, please visit www.veratx.com.

Faces of IgA Nephropathy: Meet 3 patients living with IgAN – https://veratx.com/patients/#igan

LinkedIn – https://www.linkedin.com/company/veratx/

Twitter – https://twitter.com/veratx2